What Do You Want to Know? A Reader's Survey Tells All
Learn what Applied Clinical Trial's readers told us in our annual reader's survey.
What Do You Want to Know? A Reader's Survey Tells AllDid you respond to Applied Clinical Trials' reader survey this year? Well, the results are in and those of you who did respond gave us an inside look into what clinical trials professionals are planning for their businesses in the next year and what they want to learn more about both in print and online.
New strategies that respondent's organizations would be undertaking in the next year to remain competitive included increasing efficiencies with technology (70%) and forming partnerships (58%). The hot topics that people want addressed in the next year are good clinical practice (64%), economic impact on the industry (43%), and eClinical (43%).Delving deeper into article topics, respondents want to see more on regulations, Phase II-III trials, education and training, Phase IV trials/postmarketing, and biotechnology.Check out page 8 to see the lucky respondent who won a flat screen television for participating in Applied Clinical Trials' survey this year.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
First Patient Dosed in Phase III Trial of Enhertu as First-Line Treatment for Endometrial Cancer
June 10th 2025In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair proficient primary advanced or recurrent endometrial cancer.
